| ISMagazine.com | Medicine, Health, and Fitness |
June, 1999 |
KIRKLAND, Quebec, May 13, CryoCath Technologies Inc., the world's leading developer of cryoablation catheter technology (i.e. the use of cold energy via catheters to therapeutically ablate tissue), today announced that it has received Canadian regulatory approval to expand its human clinical studies for supraventricular tachycardias (SVT's) to a second Canadian clinical site and an additional 30 patients. This approval follows a successful 12 patient feasibility study at the Montreal Heart Institute (ICM) for AV Node ablation with CryoCath's FreezorT focal ablation catheter system.
Dr. Marc Dubuc, Chief of Electrophysiology at the ICM and principal investigator for CryoCath said, ``We were very pleased with the results of this first ever human use of cryoablation catheter technology to treat cardiac arrhythmia and are excited about the long term prospects''. Dr. George Klein, Chief of Cardiology at University Hospital in London, Ontario said, ``We are
looking forward to evaluating CryoCath's new system at our center. Catheter
cryoablation technology potentially offers innovative and more effective ways of treating
both routine and more difficult cardiac arrhythmia cases''.
Dr. Don Larnard, Chief Technology Officer of CryoCath Technologies, commented ``Results from our extensive animal testing and initial clinical experience have provided our development teams with encouraging feedback to not only move this product to expanded clinical trials, but to enhance our newer electrophysiology developments for treating other arrhythmia applications.''
Mr. Steven G. Arless, President and CEO of CryoCath Technologies Inc. further commented ``This initial experience of our technology in humans is another critical step in our quest to find a treatment for Atrial Fibrillation and Ventricular Tachycardia. The completion of our initial pilot study and the start of the second trial, paves the way for extended use of this technology in Canada, Europe and in the USA''.
INITIAL PRODUCT:
CryoCath's initial product is a Cardiac Cryoablation Catheter System for use in electrophysiology, an area of cardiology specializing in the treatment of heart arrhythmias (irregular heartbeats). This system, which
ABOUT CRYOCATH:
CryoCath Technologies Inc. is the world leader in developing and bringing to market a family of innovative cryoablation catheters and consoles, which safely, precisely and effectively apply cold energy to problem tissue areas. Through this proprietary cryoablation technology, CryoCath offers cost-effective and minimally invasive treatment solutions for heart arrhythmias and other interventional applications. For further information, contact CryoCath President and CEO, Mr. Steven G. Arless at sarless(at)cryocath.com, by telephone at (514) 694-1212, or refer to the CryoCath website at http://www.cryocath.com.
BioLogix and BigOnline to Build Medical Community
SAN FRANCISCO, May 13 -- BioLogix International, Ltd. (OTC Bulletin Board: BGIX) reported today that it has entered into an exclusive development agreement with BigOnline (http://www.bigonline.com) to build a medical community for its Internet subsidiary The MED TEL Corporation (http://www.medtel.net). The move bolsters the Company's already strong competitive position within the e-health portal industry by adding a physician and provider network to its consumer-based health supersite (http://www.thehealthchannel.com) and world of virtual health and medical reality (http://www.virtucare.com).
"We now look to more rapidly build our provider network, helping to put those who need health care and advice the most in touch with those who can now be even more empowered to give it," said BioLogix Chairman and CEO, Michael Grandon. "BigOnline has developed a set of straightforward, easy-to-use tools which completely demystify the Internet for medical professionals, who may not have either the time or inclination to get on-line themselves. Everything they need is already provided."